Grantee Spotlight: Developing New ImmuneBased Treatments for Aggressive Brain Cancer
Grantee Spotlight: Developing New Immune-Based Treatments for Aggressive Brain Cancer March 24, 2026 The Challenge Malignant brain tumors, such as glioblastoma, are among the most aggressive cancers in adults. Despite maximal standard therapy – surgery followed by radiotherapy and temozolomide chemotherapy – most patients live only about 15 to 16 months after diagnosis. For decades, progress has been slow, and new treatment approaches are […]
Grantee Spotlight: Developing New ImmuneBased Treatments for Aggressive Brain Cancer Read More »








